Who are Lactobacillus Crispatus M247's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): lactobacillus LB, INF108F probiotic, Lactobacillus casei variety rhamnosus granules, E. coli Nissle suspension, Lcr Regenerans, EcN-Suspension.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lactobacillus-crispatus-m247.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lactobacillus Crispatus M247 — Competitive Intelligence Brief

Lactobacillus Crispatus M247 (Lactobacillus Crispatus M247) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live biotherapeutic product. Area: Infectious Disease / Women's Health.

marketed Live biotherapeutic product Infectious Disease / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Lactobacillus Crispatus M247 (Lactobacillus Crispatus M247) — Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Lactobacillus crispatus M247 is a live biotherapeutic agent that restores and maintains a healthy vaginal microbiome by colonizing the vaginal tract with beneficial lactobacilli.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Lactobacillus Crispatus M247 TARGET	Lactobacillus Crispatus M247	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Live biotherapeutic product
lactobacillus LB	lactobacillus LB	Hospital General de Mexico	marketed	Live biotherapeutic product / Probiotic
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)
Lactobacillus casei variety rhamnosus granules	Lactobacillus casei variety rhamnosus granules	Seoul National University Hospital	marketed	Probiotic / Live biotherapeutic product
E. coli Nissle suspension	E. coli Nissle suspension	University of Hohenheim	marketed	Live biotherapeutic product (probiotic)
Lcr Regenerans	Lcr Regenerans	Probionov	phase 3	Live biotherapeutic product (LBP)
EcN-Suspension	EcN-Suspension	Ardeypharm GmbH	phase 3	Live biotherapeutic product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live biotherapeutic product class)

Ardeypharm GmbH · 1 drug in this class
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 drug in this class
Infant Bacterial Therapeutics · 1 drug in this class
Mikrobiomik Healthcare Company S.L. · 1 drug in this class
OxThera · 1 drug in this class
Rebiotix Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lactobacillus Crispatus M247 — Competitive Intelligence Brief. https://druglandscape.com/ci/lactobacillus-crispatus-m247. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab